Biofrontera AG: Biofrontera AG signs an agreement with Propharma d.o.o. for the distribution of Ameluz® in Croatia

Leverkusen (pta012/04.11.2025/10:20 UTC+1)

• Biofrontera Pharma GmbH, the main commercial subsidiary of Biofrontera AG, provides the rights for promotion and distribution to Croatian pharma company Propharma d.o.o. to commercialise Ameluz® in the Croatian territory.
• Propharma d.o.o. will seek for reimbursement of the product.
• Subject to a successful outcome of reimbursement discussions, Propharma will likely start selling the product towards the end of 2026.

Leverkusen, November 4th 2025 – Biofrontera Pharma GmbH, the main commercial subsidiary of Biofrontera AG, a German biopharmaceutical company specialized in the development and commercialization of dermatological prescription products, today announced the closing of a promotion and distribution agreement with Propharma d.o.o., to commercialise Ameluz® in Croatia.

With more than 25 years of experience managing prescription products in the Croatian market, Propharma d.o.o. has established itself as a trusted partner serving both the retail and hospital segments.

As part of the partnership, Propharma will pursue reimbursement approvalfor Ameluz® from the Croatian healthcare system. Once reimbursement is secured, Propharma will lead the promotion and distribution of the product across Croatia, leveraging its dedicated resources and experienced commercial teams to reach healthcare professionals nationwide.

Ameluz® as a first available PDT-treatment will come as a unique opportunity where very few options to pharmacologically treat Actinic keratosis exist so far. Biofrontera will receive a transfer price based on Propharma's net revenues.

"We are pleased to have found a matching partner for Ameluz® to provide a new option for Croatian patients to treat Actinic keratosis and Basal Cell Carcinoma* which represent common skin diseases of the Croatian population," said Axel Drews, VP Global Marketing & Sales of Biofrontera Pharma GmbH. "The agreement complements our strategy of focussing on the European market in order to generate sustainable growth and profitability by fully exploring our key product Ameluz®.

*Ameluz® 78mg/g gel is indicated for the treatment of actinic keratosis of mild to moderate severity (Olsen grade 1 to 2) and of field cancerization in adults and for the treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due to possible treatment-related morbidity and/or poor cosmetic outcome in adults. For full prescribing information, please refer to the Summary of Product Characteristics (SmPC) of the product.

(end)

Emitter:	Biofrontera AG Hemmelrather Weg 201 51377 Leverkusen Germany
Contact Person:	Investor Relations
Phone:	+49 (0) 214 87 63 20
E-Mail:	ir@biofrontera.com
Website:	www.biofrontera.com
ISIN(s):	DE000A4BGGM7 (Share)
Stock Exchange(s):	Regulated Market in Dusseldorf, Frankfurt; Free Market in Berlin, Munich, Stuttgart, Tradegate